FindTrial
Sign In

Trastuzumab and Pertuzumab

DRUG2 trials

Sponsors

American Society of Clinical Oncology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Conditions

Adjuvant Treatment After TrastuzumabAdvanced Solid TumorsEarly-stage Breast CancerHER2-positive Breast CancerLymphoma, Non-HodgkinMultiple MyelomaNeratiniRCB Classification 1-2

Phase 2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecruitingNCT02693535
American Society of Clinical OncologyAdvanced Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma
Start: 2016-03-14End: 2028-12-31Target: 4200Updated: 2026-05-29

Phase 3

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
RecruitingNCT05760612
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAdjuvant Treatment After Trastuzumab, Early-stage Breast Cancer, HER2-positive Breast Cancer +2
Start: 2023-03-14End: 2028-11-01Target: 300Updated: 2025-09-25

Related Papers

Atezolizumab (A) plus pertuzumab/trastuzumab/hyaluronidase (PHESGO) in patients (pts) with solid tumors with <i>ERBB2</i> alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2026-05-27
Tucatinib + subcutaneous (SC) trastuzumab (Tuc + Trast SC) in patients (pts) with solid tumors with <i>ERBB2</i> alterations (alts): Results from the targeted agent and profiling utilization registry (TAPUR) study.
Journal of Clinical Oncology2026-05-27
Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 alterations (alts): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2026-01-10
Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study.
2025-07-03
Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2025-05-281 citations
Pertuzumab plus trastuzumab (P+T) in patients (pts) with bladder (BC) and ovarian cancer (OC) with <i>ERBB2/3</i> alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2025-05-28
Nivolumab plus ipilimumab (N+I) in patients (pts) with pancreatic cancer (PC) with <i>BRCA1/2</i> mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2025-01-273 citations
Afatinib in patients (pts) with solid tumors with neuregulin 1 (<i>NRG1</i>) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2024-06-011 citations
Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with <i>ERBB2</i>or<i> ERBB3</i>amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2024-06-01
Nivolumab plus ipilimumab (N+I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Journal of Clinical Oncology2024-06-01
Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with <i>BRCA1/2</i> mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2024-01-201 citations
Abemaciclib in patients (pts) with esophageal cancer (EC) with <i>CDKN2A</i> loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2024-01-20
The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial
Clinical Trials2023-07-257 citations
Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with <i>BRCA1/2</i> mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2023-06-011 citations
Temsirolimus (T) in patients (pts) with solid tumors with <i>PIK3CA </i>mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2023-06-011 citations
Talazoparib (Tala) in patients (pts) with solid tumors with <i>BRCA1/2 </i>mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2023-06-011 citations
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
BMC Cancer2023-02-2223 citations
Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2023-01-247 citations
Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Journal of Clinical Oncology2023-01-247 citations
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
npj Precision Oncology2022-10-2715 citations

19 more papers not shown